LUPRON Drug Patent Profile
✉ Email this page to a colleague
When do Lupron patents expire, and when can generic versions of Lupron launch?
Lupron is a drug marketed by Abbvie Endocrine Inc and is included in six NDAs. There are two patents protecting this drug.
The generic ingredient in LUPRON is leuprolide acetate. There are twenty-two drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lupron
A generic version of LUPRON was approved as leuprolide acetate by SANDOZ on August 4th, 1998.
Summary for LUPRON
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 57 |
Clinical Trials: | 132 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for LUPRON |
DailyMed Link: | LUPRON at DailyMed |
Recent Clinical Trials for LUPRON
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Emory University | Phase 4 |
National Cancer Institute (NCI) | Phase 4 |
Syneos Health | Phase 2 |
US Patents and Regulatory Information for LUPRON
Expired US Patents for LUPRON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie Endocrine Inc | LUPRON | leuprolide acetate | INJECTABLE;INJECTION | 019010-001 | Apr 9, 1985 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LUPRON
See the table below for patents covering LUPRON around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Bulgaria | 60340 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |